(Reuters) -British stocks closed lower on Wednesday as losses in healthcare and real estate shares offset positive trade talk ...

Adding tumor-bed biopsy to trimodality imaging after neoadjuvant chemotherapy did not reliably predict pathological complete ...

Afatinib has broad activity against EGFR mutations. However, the approval for uncommon mutations was based on data from 38 ...

AstraZeneca (AZN) and Daiichi Sankyo (DSNKY) announce that Enhertu hit the main goal in a Phase 3 trial for early-stage ...

Less than three weeks after AstraZeneca and Daiichi Sankyo reported positive results for oncology powerhouse Enhertu in a ...

Astrazeneca could be opening a new facility in Rockville.

Lupus patients, advocates, and medical experts gathered Thursday for the observation of World Lupus Day on May 10 to put the ...

AstraZeneca and Daiichi Sankyo's anti-HER2 drug Enhertu has been shown to provide a benefit in a phase 3 trial in early-stage ...

The biggest strategic highlight for Tempus AI Inc. (NASDAQ: TEM) during the first quarter was a multi-million dollar deal to build "the world's largest foundation model for oncology." ...

Topline results from the Phase III DESTINY-Breast11 trial show that Enhertu (trastuzumab deruxtecan) followed by paclitaxel, ...

Vivo Capital ("Vivo" or "the Firm"), a leading global investment firm focused exclusively on healthcare and life sciences, ...

During a live event, Ahmad Tarhini, MD, PhD, discussed the RELATIVITY-047 trial of nivolumab/relatlimab vs nivolumab alone in ...